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EFFICACY OF PHARMACOLOGICAL AGENTS ON THE REMISSION 
INDUCTION AND MAINTENANCE OF CROHN’S DISEASE 
 
JEFFREY FAROOQ 
ABSTRACT 
The two options for treatment of the inflammatory bowel disease Crohn’s Disease 
are surgery and pharmacotherapy. Pharmacotherapy with the goal of inducing and 
maintaining remission is the preferred treatment route, but the current medications are not 
entirely effective in achieving these goals. Approximately half of Crohn’s Disease 
patients will be required to have surgical bowel resection within 20 years of diagnosis, 
and many patients are at higher risk of adverse events such as cancer, either directly as a 
result of Crohn’s Disease or due to side-effects of the drugs used to treat the condition.  
Medical management of the disease is very complicated and there is a relative 
lack of uniformity in treatment. Different drugs used either in monotherapy, sequential 
therapy, or combination therapy produce differing levels of efficacy and different 
outcomes. This analysis provides an overview of the four major classes of drugs used in 
the treatment of Crohn’s Disease and a discussion of the overall efficacy of the different 
methods of treatment. While more studies need to be conducted into the differing 
outcomes of monotherapy, sequential therapy, and combination therapy, it appears as 
though any treatment involving the use of biologics such as tumor necrosis factor alpha 
(TNF-alpha) inhibitors results in improved outcomes relative to treatment styles that lack 
the use of biologics.  
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INTRODUCTION 
The incidence of gastrointestinal diseases in developed civilizations has rapidly 
increased in the last century, prompting an increase in research focused on elucidating 
mechanisms and therapeutics for the treatment of these ailments. Crohn’s Disease, a type 
of Inflammatory Bowel Disease, is one such gastrointestinal condition. Crohn’s Disease 
is characterized by inflammation within any portion of the gastrointestinal tract, resulting 
in a number of serious side effects that, if left untreated, can severely impact day-to-day 
functioning and overall quality of life.   
Key signs and symptoms of Crohn’s Disease include the development of ulcers in 
the gastrointestinal tract, malabsorption, and painful inflammation of the intestines. 
Commonly, resection of the bowel is used as a necessary intervention to prevent and 
manage these damaging adverse effects. To date, there is no cure for Crohn’s Disease and 
all available treatments are focused on putting patients in both clinical and endoscopic 
remission. While currently available treatments often yield only partially successful 
results in inducing remission of Crohn’s Disease, extensive progress has been made in 
recent years allowing for improved chronic disease management of CD. Further adding to 
the difficulty of finding cures and 100% effective treatment regimens is an incomplete 
understanding behind the molecular mechanisms of Crohn’s Disease. As a result, current 
first-line therapies mainly focus on reducing and managing symptoms of Crohn’s 
Disease, rather than treating the root cause of CD. Common methods of treatment 
currently aim to induce and maintain remission of CD symptoms through the use of anti-
inflammatory agents or immunosuppressants.   
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 The therapeutic armamentarium for Crohn’s Disease includes corticosteroids, 
thiopurines, methotrexate, and the biologic agents (including TNF-alpha inhibitors, an 
anti-integrin molecule, and an IL 12/23 inhibitor). These drugs have traditionally been 
used in the treatment of other diseases, including cancer and arthritis, but have also been 
demonstrated to attenuate the severity of the symptoms of Crohn’s Disease. Usually, 
these drugs accomplish this by reducing the level of intestinal inflammation or by acting 
as immunomodulators. Although not 100% effective in all patients, the use of these 
medications has led to clinical improvement in nearly 70% of patients (Present et al., 
1980).  More recent clinical trials involving more advanced formulations of these 
medications, such as the administration of a novel delayed-release formulation of 
thiopurines, have shown to be potentially more efficacious than previous formulations 
(Israeli et al., 2015). Current research is also continuing to further improve standard 
formulations of these drugs, with the goal of improving efficacy and safety, enabling 
easier patient adherence to medication regimens, and reducing adverse events. A recent 
2015 clinical trial illustrated the improved safety and efficacy profile of an oral, fixed-
dose, delayed-release thiopurine formulation compared to standard thiopurine 
formulations (Israeli et al., 2015),  
 Nevertheless, continued use of current pharmacotherapeutic options as a long-
term treatment pose numerous risks to patients and ultimately, reduce its viability as a 
long-lasting option in the treatment of Crohn’s Disease. Treatment with thiopurines and 
TNF-alpha inhibitors have led to toxicity and significant detrimental side effects in at 
least 15% of patients, forcing those patients to discontinue treatment (Qiu et al., 2015). 
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Prolonged use of thiopurines, for example, has also been associated with suppression of 
white and red blood cell levels, liver and bone marrow toxicity, and inflammation of the 
pancreas. Research on the effectiveness of monotherapies in the treatment of Crohn’s is 
inconclusive. One 2014 study showed that long-term treatment using a thiopurine 
monotherapy maintained remission in less than 25% of patients after 12 months (Boyle et 
al., 2014). Another 2016 study found that 73% of patients had remained in remission 
after a mean 42 month follow-up following an TNF-alpha inhibitor monotherapy, with an 
estimated 57.9% cumulative probability of remaining in remission after a five year period 
(Peyrin-Biroulet et al., 2016). These findings suggest that the effectiveness of 
monotherapies should be evaluated on a drug-specific basis. Additionally, other research 
has also suggested that combination therapies may be more effective in maintaining 
remission of CD, while also partially mitigating the higher adverse effects associated 
with lower doses of each individual drug in the combination treatment (Hoentjen et al., 
2013). Notably, the effectiveness of combination therapy may be outweighed by 
currently limited knowledge of long-term side effects in addition to known knowledge of 
risks, especially those associated with opportunistic infections and cancers (Sultan et al., 
2017).  
 
History of Crohn’s Disease 
 The earliest recorded diagnosis of Crohn’s Disease dates back to 1932, when a 
group of physicians noted significant ulceration and inflammation in the ileocecal region 
of the intestinal walls in a series of patients they were providing care for (Crohn, 1932). 
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In subsequent years, additional cases with similar characteristics were reported in 
different locations of the gastrointestinal (GI) tract. Although Crohn’s Disease had 
existed as a reported, uncharacterized illness as early as the 1700s, these findings were 
critical to the designation of these symptoms as diagnostic markers for Crohn’s Disease 
(Kirsner, 1988). A majority of cases were reported in young adults, who had presented to 
their physician with symptoms of fever and GI distress.  
Limited medical knowledge regarding the pathology of Crohn’s Disease made 
development of pharmaceutical interventions difficult, effectively making surgical 
intervention the only available treatment for a number of decades (Aufses, 2001). 
Pharmacological treatment began in the 1960s, and initially produced somewhat mixed 
results. Currently, pharmacological intervention often involves some combination or 
series of corticosteroids, anti-inflammatories, and immunosuppressants. Non-surgical 
therapies have been able to achieve a reduction in symptoms and induce remission of 
Crohn’s Disease, but a true cure for Crohn’s Disease has still yet to be discovered. 
Achieving remission is a critical game changer for patients suffering from Crohn’s 
Disease, the cumulative effects of lifelong pharmacotherapy also presents its own 
challenges, both in regards to patient health and as a financial burden.   
Crohn’s Disease is a chronic condition which cycles through periods of active 
disease and transient remission. It is not entirely clear what controls the cyclic nature of 
the disease, though studies have shown a strong association between disease activity and 
environment (Ananthakrishnan, 2014). In addition, researchers have been able to identify 
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a number of single nucleotide polymorphisms (SNPs) and genetic loci related to disease 
progression (Jostins, et al., 2012).  
 In the past, Crohn’s Disease has typically been diagnosed in higher rates 
Westernized nations, including the United States and the United Kingdom. Prevalence 
studies have shown the disease to affect approximately 0.3% of the population in these 
countries. Interestingly, while the incidence rate has been steady or declining in these 
Westernized nations, countries such as Brazil and Taiwan have experienced up to 10% 
higher rates of Crohn’s Disease incidence compared to historical trends (Ng, 2017). 
 
Clinical Manifestations 
 The clinical knowledge, including the signs and symptoms, of Crohn’s Disease 
have become well characterized over the last century. Importantly, Crohn’s Disease can 
occur anywhere along the GI tract, beginning in the oral cavity and ending in the anus. It 
can also affect more than one location in the GI tract simultaneously. Terminal ileal 
involvement is common, though not always present (Friedman, et al. 2018). Endoscopic 
examination, such as a colonoscopy, as well as radiographic examination is often used to 
determine the extent of the disease spread within the GI tract. Patients often present with 
increased bowel movements, chronic diarrhea, incomplete evacuation, and bloody stool. 
Fistulas and fissures may develop in these patients, especially in the perianal region, 
although are not strictly limited to this region. Additionally, Crohn’s Disease patients 
with ileal disease commonly present to the clinic with cyclic right lower quadrant 
abdominal pain and cramping, resulting from inflammatory processes in the intestines. A 
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number of extraintestinal symptoms are often observed as well. Examples include 
osteoporosis, liver steatosis, gallstones, and ankylosing spondylitis (Ha & Khalil, 2015; 
Ranasinghe & Hsu, 2019). In addition, patients frequently complain of fatigue, due to a 
combination of anemia and malabsorption of nutrients secondary to intestinal damage. 
Decreased energy levels may also be a result of incomplete vitamin B absorption. In 
addition to these general symptoms, there are specific postprandial symptoms, such as 
bloating and loud borborygmi (Papadakis et al., 2019).  
The intestinal walls of the patient are affected by ulceration, the presentation of 
which changes depending of the severity of the disease. In high disease severity cases, 
there is usually ulcerative fusing, which creates the characteristic cobblestone appearance 
of Crohn’s Disease (Friedman, et al. 2018). When combined with the inflammatory 
processes occurring in the intestines, it is common for patients to experience narrowing of 
the intestines and subsequent bowel obstructions. Crohn’s Disease cases associated with 
high levels of inflammatory activity in the small intestine can result in destruction of the 
intestinal surface, leading to a loss in absorptive surface area. As a result, Crohn’s 
Disease is a gateway to a number of nutrient deficiencies that precede other illnesses such 
as hypocalcemia, hypoalbuminemia, and iron deficiency. Pellagra, fractures, and 
neurological issues can also occur due to nutrient deficiencies (Friedman et al., 2018).  
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Figure 1. Spectrum of the Symptoms of CD and Complications Associated with CD.  
Adapted from Crohnsandcolitis.com.4 
  
On a molecular level, a distinguishing histological feature of Crohn’ Disease is 
the presence of granulomas, collections of immune cells, such as lymphocytes and 
macrophages, which block off local areas that the immune system has determined to be 
foreign, but is then unable to phagocytose (Soler and Bernaudin, 1993). These 
granulomas can also be seen in the mesentery, lymph nodes, and peritoneum. As a result, 
the formation of a palpable masses and extended inflammation may occur in the 
abdominal area. Fistulas may also be formed by deep-penetrating fissures that perforate 
the bowel wall (Friedman et al., 2018).  
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Figure 2. Histological view of granulomas in Crohn’s Disease. This section of 
tissue was taken from the stomach and stained with hematoxylin and eosin dye. 
Note the conglomeration of immune cells around the granulomas. (Taken from 
Fakhoury et al., 2014) 
 
Pathogenesis 
Although much progress has been made in recent decades in the knowledge and 
treatment of Crohn’s Disease, much remains unknown about the mechanism through 
which it occurs and operates. It is generally agreed within the scientific community that 
there is a large immune system component, with likelihood of disease development being 
related to a combination of genetics and environment. Fortunately, an improved 
understanding of the immune system component of Crohn’s Disease pathogenesis has 
allowed for the development and application of therapeutics for Crohn’s Disease and 
subsequent improved health and quality of life for patients.   
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There is a delicate balance between impenetrability and permeability that the 
intestines must achieve (Figure 3). In order to facilitate nutrient absorption, the intestines 
must have the capacity to transport molecules as large as monosaccharides and tripeptides 
(Catnach et al., 1994) across the intestinal barrier. At the same time, the intestinal wall 
must remain secure enough to prevent the trillions of gut microbiota from entering the 
systemic circulation. Studies have noted abnormalities in the levels of specific bacteria of 
the gut microbiome in Crohn’s Disease patients (Frank et al., 2007). Importantly, the 
bacteria found to be dysregulated have been shown to have anti-inflammatory activity 
(Nishida et al., 2018). This imbalance of gut microbiota may play a role in the initial and 
ongoing pathogenesis of the disease, although this link is not entirely clear given that 
these findings were only present in a small subset of patients.  
 
 
Figure 3. Overview of the GI tract cell-microbiome interaction in Crohn’s 
Disease. The penetration of the cellular barrier lining the GI tract by microbiota 
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results in the activation of an immunological response which begins the cyclic 
process of inflammation and development of granulomas seen in Crohn’s Disease. 
(taken from Fakhoury et al., 2014) 
 
Given the importance of this balance between impenetrability and permeability, 
there is high immune system surveillance in the GI tract, with several specialized immune 
cells and structures found exclusively in the intestines (Segal, 2016). It is the 
dysregulation of the innate immune system that has often been implicated in Crohn’s 
Disease. Through an incompletely elucidated mechanism, innate immunity is essentially 
continuously activated in Crohn’s Disease, producing a chronic inflammation in the 
afflicted locations. Research on p21Rac1 guanosine triphosphatase signaling has 
suggested that suppressed p21Rac1 activity allows the innate immune system to achieve 
enhanced bactericidal activity (Parikh et al., 2014). These findings illustrate p21Rac1 
signal transduction may serve as a potential therapeutic target for inducing remission.  
Histological examination of intestinal lesions in Crohn’s Disease patients have 
showed high levels of inflammatory cell and cytokine infiltration (Rogler and Andus, 
1998). Theories posit that the conglomeration of these cells creates a positive 
inflammatory feedback loop, resulting in constant inflammation. In addition to enhanced 
inflammation, there is reduced recruitment of phagocytic neutrophils to inflammatory 
sites, resulting in decreased clearance of cellular debris (Hayee et al., 2015). This 
inability of the innate immune system to provide adequate clearance of foreign debris has 
been hypothesized to lead to the formation of the granulomas that are observed in 
Crohn’s Disease patients. This theory is also supported by research that has shown a 
potential immunodeficiency of macrophages in Crohn’s Disease patients (Casanova and 
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Abel, 2009). Macrophages are responsible for both phagocytosis and for signaling for 
neutrophils to arrive to the inflammatory site. The mechanism of macrophage defect is 
due to macrophages being unable to effectively exocytose their intracellular cytokines, 
including those that attract neutrophils (Hayee et al, 2015).  
Further underscoring the characterization of Crohn’s Disease as an 
immunodeficiency condition, is the fact that the inflammatory response to controlled 
levels of bacterial inoculum is lower in Crohn’s Disease patients than in normal healthy 
subjects. Immune response to low levels of bacterial inoculate was not significantly 
different between Crohn’s Disease patients and healthy controls (Hayee et al., 2015). 
This shows that the immune system in Crohn’s Disease patients may operate normally 
under some circumstances, but a sufficient bacterial load can push the weaker immune 
system beyond what it is capable of handling, initiating the chronic inflammation loop 
and the formation of the granuloma.  
The adaptive immune system is also involved in the pathogenesis and progression 
of Crohn’s Disease. The delayed clearance of debris by the immune system, resulting 
from incomplete macrophage and neutrophil phagocytic activity, may be a trigger for the 
T-cell response that is often observed (Sewell et al., 2009). It is important to note that 
although macrophages in Crohn’s Disease patients do not release inflammatory cytokines 
(such as TNF-alpha) as effectively as healthy macrophages, the accruement of immune 
cells in the granulomas results in overall elevated TNF-alpha levels (Dai et al., 2015). 
The significance of this is that Crohn’s Disease proceeds through two phases, one marked 
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by sub-threshold immune activity, and the second marked by supra-threshold immune 
activity that causes tissue damage and destruction. 
 
General Outcomes 
While Crohn’s Disease itself is not considered a fatal disease, it remains an 
incurable chronic condition, which individuals must adapt to and live with throughout 
their life course. While pharmacotherapies are some of the most effective means of 
treating and managing Crohn’s Disease symptoms, there are some negative cumulative 
effects of chronic inflammation and pharmacological therapy. A large 2003 study on the 
mortality of Crohn’s Disease had shown increased mortality rate compared to healthy 
patients. Over the course of the study, elderly Crohn’s Disease patients experienced the 
outcome of death 73% more often than the healthy subjects (Card et al., 2003). The onset 
of Crohn’s Disease usually occurs during young adulthood, with younger patients 
typically lower rates of death compared to adults. The risk of death associated with 
Crohn’s Disease increases in magnitude with age, controlling for the increased risk of 
death as a result of age alone (Card et al., 2003). However, it is important to note that 
large variability in mortality rate has been observed, partly due to limitations in study 
design. The 73% higher chance of death observed in the elderly is an upper estimate of 
mortality (Loftus, 2006).  
The chronic inflammation experienced in Crohn’s Disease leads to sustained 
tissue damage over the life course, and it is one potential mechanism through which 
cancer develops (Coussens and Werb, 2010). Cancer rates in Crohn’s Disease patients are 
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significantly higher than those observed in the general population, especially with respect 
to the regions affected specifically by the disease. In a study population of over 60,000 
patients, adults with Crohn’s Disease were found to have 28.4 times the risk of 
developing small bowel cancer and 2.4 times the risk of developing colorectal cancer, 
and compared to control patients (von Roon et al., 2007). In addition, Crohn’s Disease 
patients on thiopurine or TNF-alpha inhibitor medication regimens have been found to 
have an increased risk of developing lymphoma (Kandiel etl l., 2005), which a 2007 
study by von Roon finding a 1.42 higher risk of lymphoma in Crohn’s Disease patients 
compared to the general population (von Roon et al., 2007).These rates represent general 
data collected from patients, regardless of severity and onset of disease action. 
A final measure that is often used to understand Crohn’s Disease patient outcomes 
is the rate at which surgical intervention is needed. Within 10 years of diagnosis, nearly 
50% of Crohn’s Disease patients will undergo at least one surgery (Frolkis et al., 2013). 
A number of patients will have to undergo a second surgery within 10 years of their first 
surgery as well. There are generally two instances where surgery is performed in Crohn’s 
Disease. The first is when a patient undergoes surgery due to an immediate life threat, as 
a result of some complication, such as GI tract blockage. The rate of emergent operations 
such as this performed on Crohn’ Disease patients has declined over time by 
approximately 10% per year (Ma et al., 2017). The second type of surgical procedure 
performed is elective surgery. These operations are performed if current treatment 
options are not sufficient or if there is belief that the disease progression could result in a 
life-threatening complication in the near future. The rate of elective surgeries to treat 
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Crohn’s Disease has increased by nearly 4% per year (Ma et al., 2017). This increase in 
elective surgery rates is likely due to improved surgical treatment protocols and post-
surgical monitoring.  
It is important to note that outcome trends for Crohn’s Disease patients have been 
improving in recent years. As the medical armamentarium for treating CD continues to 
grow, surgical resection rates related to Crohn’s Disease have seen an overall decrease, 
with elective surgeries now more prevalent than emergent surgeries (Ma et al., 2017). 
This is contributed to, in part, by the development of breakthrough drugs as well as the 
discovery of prognostic and predictive factors that better guide diagnostic and treatment 
decisions. Earlier intervention, improved control of intestinal inflammation, and new 
drugs are a few of the key players that have contributed to this progress (Palmela et al., 
2015). Additionally, clinical providers have recognized there is a spectrum of severity of 
Crohn’s Disease that requires carefully tailored therapeutic strategies specific to each 
patient, to prevent overtreatment for mild cases but also to ensure more aggressive 
treatments for severe cases. A number of these treatment strategies will be discussed in 
further detail in the following sections.  
 
TREATMENT STRATEGIES 
The two primary options for the treatment of Crohn’s Disease are surgery and 
pharmacological intervention. Although surgery is a common mode of treatment, 
pharmacological intervention is generally the first-line strategy used to treat Crohn’s 
Disease. Surgery is often used as a secondary option in more severe cases, as it has the 
 15 
potential for fatal post-surgical complications. These include, but are not limited to, 
wound infections, anastomotic leaks, and anastomotic strictures (Li & Zhu, 2018). In 
addition, while diseased sections of the intestines are moved, it is possible for the disease 
to spread to further healthy bowel sections, necessitating multiple bowel resections ans 
associated risks. Importantly, there are also weaknesses associated with pharmacological 
intervention, in particular its expensive cost and association with adverse side effects. 
There are two main goals of pharmacological intervention. The first is to induce the 
remission of Crohn’s Disease such that symptoms subside. The second goal is to maintain 
remission of Crohn’s Disease for as long as possible. There are several different 
medication regimens commonly utilized to achieve this goal, each operating through 
distinct mechanisms. The following sections of this paper will focus on providing a 
review of the molecular background, mechanism of action, and evaluation of efficacy of 
the major pharmaceutical options for treating CD. Following a general understanding of 
the mechanisms of action for each major class of drugs used to treat Crohn’s Disease, 
efficacy of each drug will be analyzed by investigating outcomes of patients using each 
respective medication. 
The first class of medications that will be discussed are corticosteroids, for 
example, prednisone. These drugs are often used to control inflammation and have been 
relatively successful in the treatment of Crohn’s Disease. The second class of 
medications that is commonly used in treatment are biologics. These are drugs in the 
form of antibodies that selectively bind to and block the action of one or more targets in 
the host body. Similar to corticosteroids, these drugs help to control inflammation. The 
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third of drugs that will be discussed are thiopurines, which operate by suppressing the 
activity of the immune system. The final class of drugs are methotrexates, which have 
typically been used in the treatment of cancers, but have been successful in mitigating the 
symptoms of Crohn’s Disease as well. 
 
Corticosteroids 
Molecular Background 
Corticosteroids are synthetic pharmacological agents whose structure is derived 
from steroid hormones endogenously produced in the adrenal cortex. They are 
particularly useful in the treatment of inflammation and regulation of the immune 
response. In the past, glucocorticoids, such as prednisone, have been applied in the 
treatment of asthma and COPD, and have recently also been found to have positive 
effects in controlling Crohn’s Disease. It is important to recognize that the use of 
corticosteroids has also been associated with many adverse side effects. The most 
common side effects observed are abdominal stress, skin rash, and swelling. Adverse side 
effects have been observed in nearly one-third of patients taking these drugs (Min et al., 
2012).  
A major consideration in a physician’s choice to utilize corticosteroid intervention 
is adrenal suppression. Because corticosteroids are synthetic analogues of hormones 
naturally produced in the body, high doses of exogenous corticosteroids can induce a 
feedback loop, whereby the adrenal cortex reduces or ceases the production of 
endogenous hormones. Over a longer period of time, this can result in atrophy of the 
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adrenal cortex and loss of its functionality. This may also be the case if treatment is 
halted abruptly. This creates a dependency on exogenous corticosteroids. For similar 
reasons, corticosteroid withdrawal can occur. 
In order to facilitate a comparison of the various pharmacological treatments, it is 
important to understand how each medication operates mechanistically. Broadly, 
corticosteroids exert their function of reducing inflammation through transcriptional 
regulation downstream of the glucocorticoid receptor (GR), an intracellular nuclear 
receptor that resides in the cytoplasm (Kumar and Thompson, 2005). Upon 
glucocorticoid binding to the GR, nuclear translocation occurs and results in the 
activation of glucocorticoid response elements, therefore stimulating gene expression 
(Bledsoe et al., 2002). Importantly, among many other target cells, leukocyte 
transcription is altered by GR binding (Ashwell et al., 2000).  
Negative regulation of gene expression is also important to the anti-inflammatory 
effects of corticosteroids. In this pathway, upon glucocorticoid binding to the GR, the 
ligand-receptor complex is translocated to chromatin. The receptor-ligand complex binds 
to specific elements on the chromatin to block the transcription of NF-kB (Rogatsky and 
Ivashkiv, 2006). Normally, NF-kB upregulates the expression of certain genes that are 
involved in the pro-inflammatory process. During an immune response, such as that seen 
in Crohn’s Disease, lymphocyte activation results in the upregulation of NF-kB 
production. NF-kB exerts its effects in the nucleus through the upregulation of genes that 
stimulate the production of T-cells (Livolsi et al., 2001). However, the inhibition of NF-
kB production results in a cessation of this pathway, thereby mitigating some of the 
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inflammatory process. Thus, the pro-inflammatory genes, cytokines, and cells that are 
normally over-expressed during the chronic inflammatory process are modulated by the 
action of glucocorticoids.  
 
Figure 4. Overview of Glucocorticoid-mediated signal transduction. Upon 
ligand binding, the long-receptor complex translocates to the nucleus to exert its 
induction and repression functions. (Taken from Ramamoorthy and Cidlowski, 
2017) 
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One potential explanation for the effectiveness of glucocorticoids in treating GI 
tract diseases lies in the T-cell and GR relationship, an association that is still not fully 
understood. While studies investigating this relationship have produced conflicting 
results about T-call and GR signaling in-vivo versus in-vitro, it has been found that the 
presence of GR is necessary in order for T-cells to survive activation (Coutinho and 
Chapman, 2011). Studies in mice have shown that in the absence of the GR in T-cells, 
tissues of the GI suffered more damage in response to immune system activation, 
indicating a link between GR, T-cells, and the GI system (Brewer et al., 2003).  
Glucocorticoids also act to repress inflammation through non-genomic processes. 
By acting as ligands for several receptors other than the GR, they can also activate those 
receptors and initiate their activity. These include the phosphoinositide 3-kinase receptor, 
the mitogen-activated protein kinases, and the AKT receptor (Ramamoorthy and 
Cidlowski, 2017). The result of the activation of these receptors is a much more rapid 
reduction in inflammatory activity, on the order of seconds to minutes.  
Pharmacological glucocorticoids generally have greater bioavailability than their 
endogenously produced analogues. Along with higher affinity for the GR and poor 
metabolism of synthetic glucocorticoids by the body, they remain in the plasma and exert 
their effects for long durations of time. The relatively stable, long exposure to 
glucocorticoids allows these agents to modulate macrophage activity, increasing the 
efficiency with which macrophages can phagocytose their target cells (Coutinho and 
Chapman, 2011). Thus, they are very potent in controlling inflammation, especially in a 
Crohn’s Disease, which has been characterized by mechanisms of macrophage defect. 
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Efficacy  
We will begin our efficacy analysis by discussing the outcomes of Crohn’s 
Disease patients placed on a regimen of corticosteroids. It is important to evaluate clinical 
outcomes in the context of mechanisms and adverse effects, in order to form a holistic 
understanding of the drug treatment. It is also important to understand that research 
surrounding Crohn’s Disease has been somewhat inconsistent, with widely varying 
outcomes between studies.  
As previously mentioned, corticosteroids are not often employed for maintenance 
of remission of Crohn’s Disease symptoms. This is largely due to the fact that studies 
have not shown corticosteroids to be effective in the long-term maintenance of remission 
of Crohn’s Disease (Yang and Lichtenstein, 2002). However, they have proven to be 
effective in initiating remission of symptoms, at least on a short-term basis. For this 
reason, they are often one of the first-line treatments prescribed to Crohn’s Disease 
patients early on in disease progression, though they are generally discontinued shortly 
after remission has been achieved to avoid toxic side-effects.  
These findings were corroborated by another study which showed that the use of 
modified, slow-release glucocorticoids led to better rates of remission compared to 
placebo treatment, but had no statistically significant effect on prevention of relapse 
(Ford et al., 2011). The researchers found that the modified, slow-release corticosteroids 
actually provided less efficacy than the standard form of the drug, but the slow-release 
formulation was also associated with fewer adverse events. This illustrates the difficult 
balance in assigning Crohn’s Disease medications between deciding whether to prescribe 
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a formulation that more reliably achieves remission versus a formulation that results in 
less secondary adverse events. In situations such as this, it is likely a combination of 
physician recommendation based on the current severity of symptoms that the patient is 
experiencing combined with patient needs and choices. In a small study evaluating the 
modified-release budesonide compared to normal prednisolone, patients treated with 
budesonide achieved remission in 53% of cases, while patients treated with prednisolone 
achieved remission in 66% of cases (Rutgeerts et al., 1994). In this trial, a significantly 
lower incidence of side-effects was noted in the patients who received the modified-
release corticosteroid (33% of patients) compared to prednisolone (55% of patients).  
Researchers interested in testing a pH-modified form of budesonide found that 
nearly 56% of patients achieved remission compared to 73% in the group receiving 
prednisolone (Gross et al., 1996). The lower efficacy of budesonide has been attributed 
partly to a high first-pass effect. However, the lower efficacy was again offset by a 
significant difference in observed side effects. In the pH-modified budesonide study, only 
one-third of patients experienced adverse effects compared to more than two-thirds of 
patients taking prednisone.   
A separate study came to a conclusion that contradicted many of the 
aforementioned studies. In a study of the efficacy of slow-release budesonide compared 
to regular formulation prednisone (a precursor form of prednisolone), prednisone was 
found to have been equally as effective to budesonide in treating Crohn’s Disease of the 
terminal ileum (Bar-Meir et al., 1998). This may be due to differences in the way that 
prednisone is metabolized versus directly giving the patient the active metabolite 
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prednisolone. Nevertheless, this study did support the finding that patients taking 
budesonide experienced fewer adverse events than patients taking prednisone. In this 
study, twice as many patients experienced symptoms in the prednisone group. The 
importance of this is that budesonide has been shown to be relatively efficacious as a 
corticosteroid in inducing remission of Crohn’s Disease, achieving and efficacy higher 
than placebo and at least equal to other corticosteroids, but with less side-effects. Both 
medications exert their primary effects rapidly, with Crohn’s Disease activity decreasing 
in magnitude the greatest over the first two weeks of treatment (Bar-Meir et al., 1998). 
Further supporting the results of this study which showed equal efficacy of budesonide 
and prednisone, another study found that modified-release budesonide was similar to 
prednisolone in inducing CD remission (Campieri et al, 1997). They found that a 
remission rate of 60% was achieved regardless of which drug was given. Similar results 
on the efficacy of budesonide were also reported in a study in children (Levine et al., 
2003).  
Today, prednisone and its metabolite are still often prescribed in lieu of 
budesonide, despite the fact that the efficacy of budesonide has been shown to be more or 
less equal to prednisone and prednisolone, but with fewer side effects. This is because 
prednisone exerts its actions systemically. Crohn’s Disease is a characterized by 
abnormal immune system activity, initially localized to the GI tract that then leads to 
systemic inflammation. This is also the reason why extraintestinal symptoms are 
observed in Crohn’s Disease patients. Prednisone, because it acts systemically, is often 
used in certain cases as the first corticosteroid treatment, as it can help control these 
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extra-intestinal abnormalities. Due to the high adverse-effects profile, it is common that 
prednisone treatment is eventually discontinued in favor of budesonide, once systemic 
effects have been controlled. Budesonide acts more specifically in the GI tract, exerting 
less systemic effects than prednisone.  
While treatment with corticosteroids is often indicated for acute Crohn’s Disease 
flare-ups and induction of remission, their use remains less than ideal and calls for the 
development of safer alternatives. Serious side effects negatively impact bone health such 
as bone loss, cardiovascular health including venous thromboembolisms, and 
immunological functioning, allowing for opportunistic infections (Waljee et al., 2016). 
Importantly, the use of corticosteroid has been associated with severely increased rates of 
mortality, with one study finding Crohn’s Disease patients on corticosteroid therapy had 
2.48 times the mortality rate compared to patients not on corticosteroid therapy, over a 
ten-year period (Lewis et al., 2008). For chronic treatment and maintenance of remission, 
the adverse effects of corticosteroids make them effectively a non-viable option. In 
addition to efforts that promote research and development of safe and effective 
alternatives to corticosteroids, care should be taken to ensure physicians are kept up-to-
date on the most recent effects of the harms of corticosteroid use well prescribing 
medication regimens for Crohn’s Disease.  
 
Biologic Drugs 
Perhaps the most rapidly growing class of drugs in the treatment of Crohn’s 
Disease are the biologics, which are generally comprised of monoclonal antibodies that 
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exert their action through binding to and inhibiting the natural function of their target. 
There are three major classes of biologics that been shown to be effective in treating the 
symptoms of Crohn’s Disease: the TNF-alpha Inhibitors, the anti-integrins, and the IL-
12/23 inhibitors. The ability of these exogenous antibodies to target different molecules 
in the pathogenesis of Crohn’s Disease has given physicians important new options in 
treating their patients. 
 
Anti TNF-alpha Molecular Background 
TNF-alpha inhibitors are synthetic monoclonal IgG antibodies. Like 
glucocorticoids, these agents are particularly efficacious in treating inflammation, though 
they operate through a different mechanism. They are designed to bind to and effectively 
block endogenously produced TNF-alpha cytokines (see figure 5), reducing further 
inflammatory cascades. The blockage of TNF-alpha spares the GI tissue from damage 
and thus reduces the need for downstream surgical treatment. Infliximab, Adalimumab, 
and Certolizumab are three important TNF-alpha inhibitors that have been used in the 
treatment of Crohn’s Disease. They have proven to be relatively effective in controlling 
symptoms and inducing remission of the disease. Common side effects including 
headache, rash, infection, and anemia have been observed to occur in in more than 10% 
of patients receiving TNF-alpha inhibitors (Gerriets and Khaddour, 2019). They have 
also been linked to more serious but rare adverse events including congestive heart 
failure, lymphoma, the formation of autoimmune antibodies, and demyelinating disease 
(Scheinfeld, 2004). In fact, there is well-characterized link between combination therapy 
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involving TNF-alpha inhibitors in young males and Hepatosplenic T-cell lymphoma. 
(Parakkal et al., 2011).  
 
 
Figure 5. Antibody structure of Infliximab, Adalimumab, and Certolizumab. 
Note that Etanercept has not been implicated in the treatment of Crohn’s Disease. 
(taken from Horiuchi et al., 2010) 
 
TNF-alpha is a pro-inflammatory cytokine secreted by various cells in the innate 
and adaptive immune system. It exerts its primary immunomodulatory effects through the 
induction of the NF-kB pathway, with increased levels of TNF-alpha stimulating NF-kB 
production and activating inflammatory pathways (Mitomia et al., 2018). There are two 
forms of TNF-alpha: a soluble form and a transmembrane form. Both are involved in the 
inflammatory process, but act in different capacities. The transmembrane form is 
involved in cell-to-cell interactions involving signal transduction mechanisms, while the 
soluble form is involved in pro-inflammatory signaling in a paracrine fashion (Horiuchi 
et al., 2010). In addition, there are several different types of TNF-alpha inhibitor drugs, 
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each operating through a slightly different mechanism. Certolizumab is a monoclonal 
antibody, in which polymers of polyethylene glycol have been artificially attached to the 
antigen-binding domain of the antibody. This modification confers a number of unique 
advantages such as enhanced stability, reduced toxicity, and longer duration of action of 
the drug (Milla et al., 2012). Certolizumab is able to bind to and inhibit either membrane-
bound or free floating TNF-alpha. Similarly, both Infliximab and Adalimumab, which are 
not modified with polyethylene glycol, can bind to soluble and membrane-bound TNF-
alpha. It is hypothesized that their efficacy in treating Crohn’s Disease is due to their 
ability to activate cell lysis through the complement system (Mitoma et al., 2008).  
Complement-dependent cytotoxicity may play a significant role in granulomata-
based disease, because it results in the formation of a membrane attack complex, which 
then results in lysis of the target cell. This may explain how these drugs are able to not 
only reduce inflammation, but also induce remission of Crohn’s Disease. Antibody-
dependent cell-mediated cytotoxicity is also heavily upregulated in the presence of TNF-
alpha inhibitors, further assisting with clearance of the foreign invaders causing 
inflammation (Mitoma et al., 2018). Further, Adalimumab and Infliximab have been 
shown to be able to induce apoptosis of certain lymphocytes. This helps curb some of the 
immune response, allowing for a reduction in total inflammation.  
 
Anti TNF-alpha Efficacy 
TNF-alpha inhibitors directly reduce the level of inflammation in the GI tract by 
blocking the signaling actions of the TNF-alpha cytokine, sparing the intestinal tissue 
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from chronic damage. Healthy GI tract tissue is essential for both proper nutrient 
absorption and prevention of intestinal narrowing. Perhaps most importantly, maintaining 
healthy GI tract tissue reduces the likelihood that surgical intervention will be necessary. 
In a recent Norwegian study, an inverse relationship was identified between TNF-alpha 
inhibitor use and surgical rates. Crohn’s Disease patients living in areas with the highest 
use of TNF-alpha inhibitors had the lowest rates of surgical intervention (Lirhus et al., 
2018). This shows that the use of TNF-alpha inhibitors is efficacious in the treatment of 
Crohn’s Disease. However, it is also important to recognize that it is difficult to evaluate 
the validity of the results due to the interference of many confounding factors such as 
socioeconomic status, age of the patient, and duration of the disease. These factors could 
have potentially exaggerated the findings of the study. Moreover, the difference in TNF-
alpha inhibitor use from the highest-use region to the lowest-use region was greater than 
10.5%, while the difference in surgical rates was only 5.7%. 
In a separate study investigating the rate of surgery as a function of time, 
researchers found that the risk of a patient requiring surgery was not strongly related to 
how many years a patient was taking TNF-alpha inhibitors (Eberhardson et al., 2017). 
Although not statistically significant, there was a slightly higher incidence of cancer in 
early treatment compared to late treatment. Further, in those who are able to tolerate the 
treatment, another study found that hospitalization rate was reduced by 50% (Mao et al., 
2017). If a biomarker was discovered or screen could be developed to proactively identify 
patients that could tolerate treatment, this would greatly help clinicians decide which 
class of medications to prescribe.  
 28 
 Perplexingly, some evidence suggests that the rate of mortality of postoperative 
patients is higher in those who were using TNF-alpha inhibitors prior to surgery 
(Brouquet et al., 2018). In a recent study, among those Crohn’s Disease patients who 
were taking TNF-alpha inhibitors at least three months prior to surgical bowel resection, 
the odds of death were nearly 200% higher than that for patients who were not taking 
TNF-alpha inhibitors at least three months prior to surgery. Although it remains to be 
understood exactly why this relationship between TNF-alpha usage and postoperative 
death exists, it should certainly be taken into account before elective surgery is 
recommended. 
 Despite the positive effects that successful TNF-alpha inhibitor treatment can 
confer to patients, unfortunately not all patients are able to benefit from these drugs. 
Indicators of ineffective drug therapy include the need to escalate dose, discontinue or 
switch medications, or the need for surgical intervention. Using this criterion, it has been 
documented that TNF-alpha inhibitor treatment is not optimally effective in around 60% 
of Crohn’s Disease patients (Lindsay et al., 2017). The average time before at least one 
indicator of ineffective treatment was noted was approximately one and a half years. Of 
particular interest is the concept of TNF-alpha dose escalation and the need to switch 
medication. Although one would think that both of these are driven by the development 
of tolerance to drug treatment, a study looking at colonic gene expression concluded that 
loss of responsiveness to TNF-alpha inhibitors is not due to resistance (Luther et al., 
2018). Instead, a different group of researchers found that antibodies directed against 
TNF-alpha inhibitors block the action of the TNF-alpha inhibitors. The likelihood of a 
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person having these antibodies is related to a mutation in the FCGR3A V158F gene 
(Romero-Cara et al., 2018). Theoretically, a screen could be developed to identify 
polymorphisms in this gene, which would help inform a clinician’s decision about 
whether a TNF-alpha inhibitor would be useful, as the development of these antibodies 
against TNF-alpha inhibitors effectively ablates the efficacy of TNF-alpha inhibitor 
treatment.  
 Beyond the development of resistance, another concern with TNF-alpha inhibitor 
treatment is that patients who have been exposed to multiple different drugs of this class 
are more likely to experience postoperative disease recurrence (Collins et al., 2017). 
Approximately 15% more cases of recurrence were noted in those that were exposed to 
more than two TNF-alpha inhibitors. It is unclear whether this is due to the development 
of antibodies against TNF-alpha inhibitors. It is reasonable to believe that the multiple 
exposures may be correlated to increased chance of developing the antibodies, though 
this has yet to be confirmed.  
 Given the lack of treatment options, some effort has gone into trying to 
circumvent the loss of responsiveness to TNF-alpha inhibitors. Loss of responsiveness 
was noted in nearly 20% of patients during a one-year long study (Srinivasan et al., 
2018). In order to re-induce responsiveness to the drugs, a strategy of subjecting the 
patient to more intense drug therapy is employed. This is very similar to the concept of 
dose interval shortening, with the major difference being that reinduction therapy only 
occurs for a finite amount of time before returning to a standard dosing regimen. In a 
one-year study following patients who had exhibited loss of responsiveness, researchers 
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found that dose interval shortening and reinduction therapy were equally effective in 
preventing relapse (Srinivasan et al., 2018). Because dose interval shortening is a strategy 
that requires higher overall use of medication and reinduction therapy was shown to be 
equally as effective over a short-term period, a strong benefit in using reinduction therapy 
lies in a reduction of the financial burden on the patient and subsequent higher likelihood 
of adhering to the medication regimen. Reinduction therapy has been shown to be 
effective in several other drugs, and it may represent a good strategy in the treatment of 
Crohn’s Disease as well. 
 Overall, TNF-alpha inhibitor therapy has proven to be a fairly effective treatment 
option. In fact, patients who discontinue TNF-alpha inhibitor treatment without medical 
indication experience worse outcomes on average than those who maintain their 
prescribed medication regimen. Those who discontinued treatment had nearly 3.5 times 
the risk of experiencing a severe flare up of symptoms and greater than 5.7 times the risk 
of making a visit to the emergency department for reasons related to the disease (Wolf et 
al., 2017).  
 Untreated Crohn’s Disease often causes a sizeable decrease in body weight 
secondary to malabsorption, because of destroyed GI tissue. Historically, TNF-alpha 
inhibitors have been associated with weight gain, indicating this medication may also 
help mitigate the weight loss effects experienced by Crohn's Disease patients. One 
explanation for the weight gain is that the mucosal healing may restore the patient’s 
ability to absorb nutrients. Considerations of weight gain and weight loss become 
particularly important when discussing pediatric and adolescent patients, for whom 
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growth may be stunted if appropriate therapy and healing is not achieved. In a study 
evaluating the body composition before and after six months of treatment with TNF-
alpha inhibitors, researchers found that body mass index (BMI) increased by more than 
two points, waist circumference increased by nearly seven centimeters, and fat mass 
index increased by approximately one point (Santos et al., 1992). A more recent study 
found that 17% of pediatric patients taking TNF-alpha inhibitors experienced excessive 
weight, above and beyond what would be considered healthy (Haas et al., 2017). The 
length of time from baseline to the last follow up in this study was 30 months. While 
some of the patients who receive treatment are able to return to a normal and healthy 
body weight, others may need to be continually monitored after treatment initiation to 
help guide them towards a healthy weight. The excessive gain in weight may be due to a 
number of factors such as unhealthy eating habits established prior to treatment and 
altered gut microbiome makeup. Further research is necessary to determine which factors 
play a role and to what extent in weight modulation under this treatment strategy. 
 A similar important outcome that is improved after the initiation of TNF-alpha 
inhibitor treatment is increased insulin-like growth factor 1 (IGF-1) levels. IGF-1 levels 
are usually lower in untreated Crohn’s Disease patients than in healthy subjects. This is 
especially important in pediatric and adolescent patients, because growth may also be 
stunted in the presence of low IGF-1 levels (Laron, 2001). In particular, IGF-1 is 
important in the development of muscle and bone due to its effects on inducing protein 
synthesis and the activation of osteocytes. Thus, patients with low IGF-1 levels can be 
expected to have decreased muscle mass and bone density. Patients receiving TNF-alpha 
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inhibitor were found to have increased IGF-1 levels compared to baseline before 
treatment, which also translated to increased muscle mass and bone recovery (DeBoer et 
al., 2018). However, it is unclear whether many of these improvements noted after the 
initiation of TNF-alpha inhibitor treatment can be attributed specifically to the TNF-alpha 
inhibitor treatment, or whether these improved outcomes are simply a result of increased 
mucosal healing. In the case of the latter, this would indicate that any drug that is able to 
achieve mucosal healing can produce these observed benefits. Mechanistically speaking, 
there is no reason to believe that the action of blocking TNF-alpha signaling would lead 
to these improved outcomes. It is more likely that these outcomes are observed due to the 
mucosal healing. However, studies have not been performed to test these specific 
outcomes in patients undergoing a different route of treatment. 
 Though more investigation needs to be conducted into the field of mucosal and 
transmural healing in Crohn’s Disease patients, it is clear mucosal and transmural healing 
is important in restoring health status. Much of the focus of treatments of Crohn’s 
Disease have been focused on forcing and maintain remission. One observational study 
was conducted that followed patients receiving TNF-alpha inhibitor treatment for two 
years (Castiglione et al., 2017). Using imaging and visualization techniques, they 
observed transmural healing in approximately 25% of patients. Therefore, while TNF-
alpha inhibitors perform respectably in the context of remission, this suggests they may 
not ideal drug candidates for inducing mucosal and transmural healing. This also 
indicates that the process of healing goes beyond reducing the level of inflammation 
affecting the GI tract. It may instead be related to the disease progression at diagnosis, 
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where patients with more advanced cases of Crohn’s Disease experience less healing due 
to longer exposure and more severe tissue damage. Additional research is needed to 
clarify this relationship. 
 Compounding the issue of ineffective mucosal healing is the risk of infection. The 
use of the TNF-alpha inhibitor infliximab was associated with infections in just over 20% 
of patients over the course of one and a half years (Li et al., 2017). Viral and bacterial 
infections occurred with slightly higher incidence than fungal infections. The researchers 
also found a statistically significant relationship between failure of mucosal healing 
during treatment and the risk of infection. Again, this data appears to suggest that the 
benefits of TNF-alpha treatment is robust in those patients who can tolerate it, but for 
those who are intolerant or respond poorly to this class of drugs, there are numerous 
adverse effects related to its use. A group of researchers attempted to find a means of 
predicting whether TNF-alpha inhibitor treatment would be effective long term in 
patients. Their findings suggested that there may be a link between fluoro-2-deoxy-D-
glucose (FDG) activity measured by positron emission tomography/computed 
tomography (PET/CT) and clinical remission at 12 months post-TNF-alpha inhibitor 
therapy (Epelboym et al., 2017). This link should not be considered in clinical 
recommendations at this time, given the very small sample size of eight patients in this 
study. However, given that five of the eight patients in the study who were still in 
remission one-year post treatment initiation also displayed declines in FDG activity after 
the first TNF-alpha inhibitor treatment, further investigation into this relationship should 
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be conducted. The identification of a viable method for predicting TNF-alpha inhibitor 
tolerance is key to future treatment protocols.  
 
Anti-Integrin Molecular Background 
 In 2014, a second class of biologics was approved by the United States Food and 
Drug Administration for use in the treatment of Crohn’s Disease: anti-integrin antibodies. 
The most commonly used anti-integrin drug is Vedolizumab. This set of humanized 
antibodies contains an antigen-binding domain that targets the alpha-4-beta-7 (⍺4ꞵ7) 
integrin. Vedolizumab, like the TNF-alpha inhibitors, is also an exogenously produced 
humanized IgG monoclonal antibody. It is most commonly used in the treatment of 
patients with moderate to severe Crohn’s Disease, administered intravenously at eight-
week intervals. Due to the relatively recent approval status, not much long-term research 
has been performed on the effects of this class of antibodies on Crohn’s Disease, though 
the clinical trials and short-term studies have proven very promising. Furthermore, 
population pharmacokinetic modeling studies have predicted equal efficacy of this drug 
across all ages and multiple ethnicities (Rosario et al., 2017).  
The ⍺4ꞵ7 integrin is a transmembrane receptor that has been shown to play an 
important role in gut lymphocyte migration, particularly of memory T-cells (Cicala et al., 
2009). The binding of the Vedolizumab antibodies to integrin ⍺4ꞵ7 results in blockage of 
memory T-cell migration to inflamed GI tract sites. Blockade of the ⍺4ꞵ7 integrin has also 
been shown to have a smaller effect on B-cell, NK-cell, and eosinophil migration, though 
this effect is not as profound as is for CD4+ T-cells (Wang et al., 2010). Inhibiting T-cell 
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migration to the GI tract limits the number of T-cells that are able to release 
proinflammatory cytokines at the affected sites in the patient, thereby reducing the 
overall level of inflammation in a gut-selective manner.  
 
 
Figure 6. Mechanism of Vedolizumab Action. Vedolizumab-binding to the ⍺4ꞵ7 
integrin prevents ⍺4ꞵ7-expressing cells from binding to mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1), ultimately impeding the ability of T-cells to 
undergo extravasation (taken from Fiorino et al., 2010). 
  
Anti-Integrin Efficacy 
 The treatment of Crohn’s Disease with Vedolizumab has yielded mostly 
successful results. It is important to preface this discussion of the efficacy of 
Vedolizumab with the fact that this drug is often used as a second-line treatment, after 
TNF-alpha inhibitor therapy has failed or in patients with a more advanced progression of 
the disease. This must be considered when evaluating the rates of clinical remission 
achieved through Vedolizumab therapy. 
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 In one observational study, the rate of steroid-free clinical remission was found to 
be approximately 20% at 54 weeks (Stallmach et al., 2016). Importantly, 69 out of 127 
patients stopped vedolizumab therapy due to lack of response. A second study based in 
Germany saw similar clinical remission rates at around 25% 14-weeks into treatment 
(Baumgart et al., 2016). In a third study which recruited a cohort of more than 100 
Crohn’s Disease patients and followed them over the course of 14 weeks, nearly 50% of 
patients retained clinical responsiveness to Vedolizumab and approximately 25% 
remained in clinical remission(Shelton et al., 2015). Another study involving a cohort of 
161 patients actively receiving Vedolizumab therapy corroborated these results. In this 
study 44 patients (~27%) achieved steroid-free clinical remission at 54-weeks after 
treatment initiation (Amiot et al., 2017). The study investigators also cited a high rate of 
loss of response to the drug. One interesting aspect of studies on the efficacy of 
Vedolizumab in the induction and maintenance of remission is the consistency of the 
findings. In addition to the four studies mentioned above, a number of other studies have 
also come to similar conclusions (Sandborn et al., 2013; Feagan et al., 2013; Vivio et al., 
2016). In addition to helping patients achieve clinical remission, Vedolizumab was 
shown to improve the quality of sleep and mood in Crohn’s Disease patients, although 
these results were also consistent with TNF-alpha inhibitor treatment (Stevens et al., 
2017). Thus, despite the occurrence of some adverse events and loss of responsiveness to 
the drugs, this illustrates  the intangible benefits these medications provide to the patient,  
improving their quality of life.  
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 In terms of the safety profile of Vedolizumab for the treatment of Crohn’s 
Disease, evidence has shown a relatively low percentage of patients experience adverse 
events. A pooled-analysis study of over 1,000 patients found that infection rates were 
only 8% and rates of other adverse events were approximately 15% (Bye et al, 2017). 
Combined with findings that it does not lead to as high of a degree of 
immunosuppression as other drugs used in the treatment of Crohn’s Disease, these 
findings show Vedolizumab is safer than other drugs in its class. A separate study that 
pooled data from multiple studies found that out of 2,830 patients being treated with 
Vedolizumab, only 18 patients were diagnosed with a malignancy over the course of 4 
years (Colombel et al., 2017). These studies support the original findings of the pre-
approval clinical trials, although longer term studies still need to be conducted to evaluate 
the safety of the drug. 
 Due to the strong efficacy and safety profile of the drug, extensive effort has gone 
into trying to predict clinical responsiveness and outcomes of Vedolizumab treatment. 
Interestingly, the addition of an immunomodulatory drug to therapy with Vedolizumab 
was found to be a very strong predictor of both clinical response and remission 54-weeks 
post-treatment initiation, with an odds ratio of nearly 12 (Allegretti et al., 2017). 
Researchers also found that the commensal bacterial species Burkholderiales and 
Roseburia inulinivorans were found in higher concentrations in Crohn’s Disease patients 
who achieved remission after 14 weeks, indicating that there may be a potential 
relationship between Vedolizumab efficacy and the gut microbiome composition 
(Ananthakrishnan et al., 2017).  
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IL-12/23 Inhibitors Molecular Background 
 One of the most recent pharmacological agents to be approved for the treatment 
of Crohn’s Disease is the biologic Ustekinumab. Like the TNF-alpha inhibitors and the 
anti-integrins, this drug is an injectable monoclonal IgG antibody. The biological targets 
of Ustekinumab are the IL-12 and the IL-23 cytokines. Both of these cytokines play 
important roles in the pathogenesis of Crohn’s Disease by acting as proinflammatory 
signalling molecules, promoting the differentiation of T-cells and the production of TNF-
alpha (Monteleone et al., 1997; Duerr et al., 2006).  
Ustekinumab neutralizes these two key inflammatory cytokines by binding to 
their p40 subunits, preventing them from binding to their respective receptors (Adedokun 
et al., 2018). Therefore, the action of Ustekinumab is very similar to Vedolizumab and 
the TNF-alpha inhibitors, albeit at a different step in the inflammatory pathway. It is also 
important to note that Ustekinumab was specifically approved for the treatment of 
moderate to severe Crohn’s Disease, in adults who have never failed treatment with TNF-
alpha inhibitors and either failed or were intolerant to first-line treatments with 
corticosteroids or immunomodulators (USFDA, 2016). It is also indicated for patients 
who failed TNF-alpha inhibitor treatment. 
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Figure 7. Mechanism of Ustekinumab Action. Ustekinumab-binding to the p40 
subunit of IL-12/23 blocks these cytokines from interacting with their endogenous 
receptors, thereby preventing them from activating their proinflammatory 
signalling cascade (taken from Deepak & Loftus, 2016). 
  
IL-12/23 Inhibitors Efficacy 
 Ustekinumab was approved for use in the treatment of Crohn’s Disease in 2016. 
Prior to its approval, a small double-blind randomized crossover control trial was 
conducted to investigate the action of Ustekinumab (Sandborn et al., 2008). Patients were 
either given placebo injections followed by Ustekinumab injections, or Ustekinumab 
injections followed by placebo injections. Crossover was separated by a washout period 
of roughly five to eight weeks. The results of this study indicated that clinical 
responsiveness to Ustekinumab was significantly higher than from placebo injections. In 
a separate pre-approval trial that focused on patients resistant to TNF-alpha inhibitors, 
researchers showed a significant improvement of Ustekinumab over placebo, in a larger 
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sample of 526 patients, finding a near 42% rate of clinical remission at week 22, 
compared to 28% for the placebo group (Sandborn et al., 2012). Infections occurred in 18 
patients, of which 10 were receiving Ustekinumab, and one case of carcinoma was 
diagnosed in a patient receiving treatment. These findings suggest strong potential for 
Ustekinumab as a treatment of Crohn’s Disease. 
While the clinical trials that preceded Ustekinumab’s approval were promising 
enough for FDA approval and  marketing authorization, additional research must be 
conducted to learn about the long-term efficacy and safety of the drug. There are a few 
key studies published that provide important insights into the future of Ustekinumab. In a 
randomized placebo-controlled trial investigating the rates of remission achieved by 
Ustekinumab in a sample of nearly 400 patients, more than 50% of patients receiving the 
Ustekinumab treatment remained in clinical remission at week 44 (Feagan et al., 2016). 
This corroborates the pre-approval clinical trial data and illustrates the high efficacy of 
Ustekinumab in inducing and maintaining remission. Furthermore, Ustekinumab was 
found to potentially induce endoscopic healing, as evidenced by improved Simplified 
Endoscopic Activity Scores in Crohn’s Disease patients receiving the drug as treatment, 
compared to placebo. 
The traditional route of administration of Ustekinumab is intravenous injection. 
However, a study investigating the efficacy of a subcutaneous administration of the drug 
found that 65% of patients with Crohn’s Disease, refractory to TNF-alpha inhibitors, 
received clinical benefit up to three months after treatment with subcutaneous 
Ustekinumab (Wils et al., 2016). A 2017 study by Ma et al. supported this finding, where 
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investigators found a 28% clinical remission rate after 12 months in patients taking 
Ustekinumab who had previously failed TNF-alpha inhibitor therapy (Ma et al., 2017). 
Importantly, this shows that Ustekinumab is able to provide clinical benefit to patients 
who have failed or become unresponsive to some first-line treatments. 
In addition to the strong clinical benefit, high responsiveness, and low adverse 
effects profile associated with Ustekinumab, recent research has also suggested that there 
may be a way to predict responsiveness to Ustekinumab treatment using fecal microbiota 
signatures (Doherty et al., 2018). This is important because the ability to use fecal 
microbiome samples as an inexpensive and valid biomarker for therapeutic 
responsiveness would allow clinicians to more quickly and accurately determine whether 
Ustekinumab would be effective for specific patients. 
  
Thiopurines 
Molecular Background 
Thiopurines are immunosuppressants often prescribed after remission of Crohn’s 
Disease has already been achieved in a patient. The goal of thiopurine treatment is to 
extend and maintain remission for as long as possible. They are useful in the treatment of 
diseases in which the immune system is overactive and targeting host cells. Historically, 
these drugs have been used in the treatment of cancers such as leukemia, but their 
effectiveness against Crohn’s Disease has allowed them gain a prominent role in CD 
treatment strategies. Commonly used thiopurines for treatment of Crohn’s Disease are 6-
mercaptopurine and azathioprine. As with any immunosuppressive drug, there are a 
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number of important adverse effects that must be appreciated and evaluated before use. 
Side-effects of thiopurine use include liver toxicity, increased risk of pancreatitis, and 
bone marrow suppression (Broekman, 2017).  
Corticosteroids and TNF-alpha inhibitors operate by blocking a specific molecule 
or cytokine involved in the immune response. They attenuate the immune response by 
reducing the availability of pro-inflammatory signals, but they do not directly interact 
with processes related to chromosomes and DNA. Thiopurines on the other hand are 
involved in an elaborate metabolism pathway which culminates in the generation of 6-
thioguanine nucleotides. These metabolites disturb the synthesis of purine nucleotides 
through the inhibition of the enzyme phosphoribosyl pyrophosphate (PRPP) 
amidotransferase, an enzyme integral to the process of purine synthesis. Overall, the 
perturbation of the PRPP amidotransferase halts the synthesis of purines, which therefore 
perturbs the synthesis of DNA (Bar et al., 2013).  
More specifically, thiopurine drugs are metabolized into deoxy 6-thioguanosine 
5’-monophosphate (TGMP) and then further into deoxy-6-thioguanosine 5’-phosphate 
(dG5). This dG5 gets incorporated into DNA, which results in apoptosis of that cell due to 
cell-cycle arrest (Cara et al., 2004). TGMP can also be converted into S-methyl-
thioinosine 5’-monophosphate (MeTIMP), which acts to inhibit purine synthesis. 
Therefore, thiopurines are able to achieve their immunosuppressive effects from two 
mechanistic approaches. First, through the generation of the 6-thioguanine nucleotides, 
thiopurines are able to induce apoptosis in immune cells. Second, the actions of MeTIMP 
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help stymie purine synthesis, preventing proliferation of new immune cells (Bar et al., 
2013).  
Another pathway through which thiopurines exert their effects is through the 
generation of a metabolite known as 6-thioguanine triphosphate (6-thio-GTP). This 
molecule has been shown to bind to Rac1, a receptor whose activation is necessary for 
the proper development to T-cells. 6-thio-GTP acts as a competitive inhibitor of Rac1, 
binding to the receptor and preventing its activation (Marinkovic et al., 2014). This 
obstructs the normal T-cell development pathway, preventing them from reaching 
maturity and therefore undergoing apoptosis. The downregulation of Rac1 activity in T-
cells also results in decreased levels of proinflammatory compounds such as TNF-alpha 
and NF-kB. However, this effect is not immediate, as it takes some time (weeks) for 6-
thio-GTP to occupy a large enough proportion of the Rac1 receptors to exert its effects in 
appreciable levels (Poppe et al., 2007). This process is also important in NK cells. 
Thiopurines have been demonstrated to target NK cells, reducing both their overall 
numbers and their Rac1 activity in Crohn’s Disease patients (Yusung et al., 2017).  
Dosing is also a very important factor to consider in the administration of 
thiopurines, because the metabolism of these drugs into metabolites varies based upon 
enzymatic activity. The level of activity of the enzymes responsible for thiopurines 
metabolism is heavily influenced by genetic polymorphisms. Thiopurine 
methyltransferase (TPMT) is the enzyme that is responsible for the conversion of TGMP 
to MeTIMP, but if there is low TMPT activity, TGMP may instead divert towards the 
pathway producing 6-thioguanine nucleotides (Cara et al., 2004). There are important 
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implications for this because there is genetic variability in TPMT activity among the 
population. In patients with wild-type TMPT activity, much more MeTIMP is produced 
in relation to 6-thioguanine nucleotides. In patients without wild-type activity of TMPT, 
there is a greater proportion of 6-thioguanine nucleotides produced, which means that 
dosage of thiopurine drugs must be scaled down to prevent toxicity from the 6-
thioguanine nucleotides (Evans et al., 1991). Nevertheless, once proper considerations of 
thiopurine dosing are taken into account, this class of drugs can be very beneficial in the 
treatment of Crohn’s Disease. 
 
Figure 8. Overview of the pathway of thiopurine metabolism. Azathioprine is 
a precursor of 6-mercaptopurine. Both are converted to 6-thioguanine nucleotides 
through a series of enzymatic transformations and degradations. (taken from Cara 
et al., 2004) 
 
Efficacy  
Mechanistically speaking, it is clear why thiopurines, which repress the immune system, 
have been used in the treatment of an autoimmune disease such as Crohn’s Disease. 
Several studies have shown favorable outcomes associated with the use of thiopurines. 
For example, one study found that the recent decline of surgical rates was correlated to 
 45 
the use of thiopurines (Lakatos et al., 2012). Another study found that the risk of needing 
a second bowel surgery was lower in those patients who were taking thiopurines than 
those who were not taking thiopurines (Guo et al., 2018). However, this finding was only 
true for patients who were already classified as being at high risk for needing a second 
surgery. Among those who were classified at low risk for needing a second surgery, no 
difference in in surgical rates was found between those who were taking thiopurines and 
who were not taking thiopurines. Given that the researchers only followed these patients 
for a 12-month time period and looked exclusively at the rate of surgery, this does not tell 
us much about the efficacy of the drug in maintaining remission for the majority of the 
Crohn’s Disease population. 
 In comparing surgical rates, it is important to contextualize a number of factors 
such as duration of treatment, duration of disease, and age of onset of disease. This is 
because previous studies have shown that the rates of surgery secondary to Crohn’s 
Disease are lower in those who were diagnosed after the age of 60 than in those who 
were diagnosed between the ages of 18 and 60 (Alexakis et al., 2017). Extended 
thiopurine use (greater than 12 months) did not impact surgery rates in elderly patients. 
This should be considered when prescribing a course of treatment for elderly patients, as 
the lack of ability of thiopurines to reduce the need for surgery combined with the 
significant adverse effects profile necessitates a risk-benefit analysis for each patient. In 
fact, the adverse effects profile is such a strong factor when considering thiopurine 
treatment that a group of investigators found that it is actually most efficacious to 
withdraw male patients from thiopurine use after the age of 40 and withdraw women 
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from usage after the age of 46 (Kirchgesner et al., 2016). The investigators drew this 
conclusion by looking at the life expectancies of patients and performing a Markov 
model assessment.  
Among the factors that affect how well a Crohn’s Disease patient tolerates 
thiopurine use is a mutation in the NUDT15 gene. This gene encodes an enzyme that is a 
negative regulator of thiopurine activation. A study found that polymorphisms in this 
gene have been associated with a poor capacity to metabolize thiopurines, leading to high 
toxicity and eventually leukopenia (Kojima et al., 2018). Though more research needs to 
be performed to more fully elucidate this effect, we know that patients with a mutation in 
this gene cannot tolerate thiopurines well. Another gene that is known to play a role in 
the ability to metabolize thiopurines is the thiopurine methyltransferase (TPMT) gene, 
which encodes the TPMT enzyme. The levels of this enzyme, which also functions in the 
metabolism of thiopurines, are able to be measured via biochemical assay or next 
generation sequencing techniques (Coelho et al., 2016). Higher levels of this enzyme are 
indicative of better thiopurine metabolism. In fact, in patients who have demonstrated 
normal activity of TPMT, it is potentially worthwhile to initiate their treatment at full-
dose capacity instead of starting at a lower dose (Benmassaoud et al., 2016). Genetic or 
biochemical screens are therefore useful in some cases to help predict how well a patient 
will tolerate thiopurines. However, there are currently no methods that predict tolerance 
with high sensitivity. A final important measurable factor that provides insight into how 
efficient thiopurine metabolism is in a patient is the levels of 6-thioguanine nucleotide. 
As discussed earlier, these are the products produced from the metabolism of thiopurine 
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drugs. A larger dose of thiopurines correlates with a higher level of 6-thioguanine 
nucleotide production. The levels of 6-thioguanine nucleotide can be used to estimate 
leukocyte count through an inverse relationship (Liu et al., 2016). This means that a 
higher 6-thioguanine nucleotide level can be used to monitor a patient’s progression to 
leukopenia. 
Two unique measurable factors that differ between patients and have been shown 
to have an effect on the metabolism of thiopurines, include blood type and smoking 
status. Recent studies have shown that those who belong to blood group B have a higher 
risk for azathioprine-induced acute pancreatitis (AIAP), though the reasons underlying 
this are not entirely clear (Teich et al., 2017). Smoking is also an independent risk factor 
for AIAP and has been shown to double the risk of AIAP (Teich et al., 2016). A related 
study investigating the ability of thiopurines to prevent postoperative relapse found that 
thiopurines only prevented relapse in patients who are classified as smokers (Mowat et 
al., 2016). While the goal of therapeutic treatment of Crohn’s Disease is to induce and 
maintain remission, smoking brings about a number of other ill effects. This makes 
clinical recommendations of a medication regimen challenging, as thiopurine-driven 
remission is better achieved in smokers, but the negative effects of smoking heavily 
outweigh the benefits associated with this treatment. More information is needed to 
understand why successful thiopurine action is improved in smokers.  
Just as in the case of TNF-alpha inhibitors, the use of thiopurines specifically in 
Crohn’s Disease patients is heavily associated with hepatosplenic T-cell lymphoma, with 
over 90% of patients who developed it having taken thiopurines at some point (Selvaraj 
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et al., 2013). Given the rarity of the disease overall, it is hard to conclusively determine 
whether there is a causal relationship between these drugs and the development of 
lymphoma or whether it is simply correlation.  
Compounding all of these issues is that conflicting reports of the efficacy of this 
class of drugs in achieving remission have been published. In a study conducted on 
Chinese Crohn’s Disease patients, researchers concluded that a 2mg/kg dose of 
azathioprine was more effective than a 1mg/kg dose (Zhang et al., 2016). They found that 
the higher dose was associated with higher rates of remission while retaining the same 
rate of adverse effects. Importantly, the study duration was less than one year, meaning 
that while no difference in short-term adverse effects was noted, no conclusions can be 
drawn on whether the higher dose increases the risk of long-term adverse events. 
However, it is reasonable to hypothesize that this would be the case. The other study 
asserted that patients taking either azathioprine or 6-mercaptopurine did not have higher 
rates of remission than those observed for patients in the placebo group (Chande et al., 
2016). This study pooled the data from thirteen different clinical trials for a total of more 
than 1,200 patients. While their analysis showed that 11% more patients taking 
thiopurines achieved clinical remission compared to those taking placebo drugs, the 
superiority of thiopurines over placebo was not statistically significant. These two 
conflicting studies bring about questions of the overall efficacy of these drugs. They seem 
to be effective in certain subsets of patients, but not effective in others. This may be why 
some smaller studies find significance in their use while larger, pooled studies do not 
reproduce these results.  
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Methotrexate 
Molecular Background 
 Methotrexate is the final drug to be discussed that is commonly used in the 
treatment of Crohn’s Disease. It has been used for a number of years to treat different 
diseases, particularly cancers. Methotrexate is an antiproliferative agent that inhibits 
dihydrofolate reductase (Rajagopalan et al., 2002), blocking DNA and RNA synthesis 
and causing the cessation of cell division and apoptosis of cells. However, a high dose of 
Methotrexate is undesirable in the treatment of Crohn’s Disease because it would produce 
the undesirable side effects associated with chemotherapy. Instead, lower doses of 
Methotrexate are used to achieve an immunomodulatory effect (Schroder & Stein et al., 
2003). It is believed that this immunomodulation occurs via increased adenosine 
concentrations, which inhibits the production of proinflammatory cytokines such as TNF-
alpha and a variety of interleukin factors (Cronstein, 1997). This is the general 
mechanism of action through which Methotrexate reduces inflammation in the body, 
alleviating inflammatory symptoms in patients suffering from Crohn’s Disease. 
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Figure 9. Mechanism of Action of Methotrexate. Treatment with Methotrexate 
leads to the increased production of Adenosine, which is thought to inhibit 
proinflammatory processes. (adapted from Pastore et al., 2015) 
 
Efficacy  
 Methotrexate has been demonstrated to have strong efficacy in maintaining 
remission of symptoms. In two separate studies, 40% of patients and 65% of patients 
were noted to have remained remission at 16-weeks and 40-weeks into treatment, 
compared to placebo (Feagan et al., 1995; Feagan et al., 2000). Another study showed 
that Methotrexate was able to maintain remission in over 40% of patients for more than 3 
years into treatment (Domenech et al., 2008). This would suggest low-dose Methotrexate 
may be good short-term treatment option due to its high efficacy in maintaining 
remission and it allows patients to be tapered off of corticosteroids, which has dangerous 
long-term adverse effects, as described earlier. However, there is some evidence 
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suggesting that Methotrexate decreases in effectiveness after approximately three to five 
years of treatment, though there are no known mechanisms for this phenomenon 
(Herfarth et al., 2017). Methotrexate is also often used in combination with TNF-alpha 
inhibitors, due to its protective effects against the formation of anti-Infliximab antibodies 
(Vermeire et al., 2007). Additionally, doses of Methotrexate larger than 12.5 mg per 
week, in combination with Methotrexate, have been shown to have higher efficacy in 
maintaining remission than doses of Methotrexate less than 12.5 mg per week (Colman & 
Rubin 2015). Therefore, not only does this combination therapy help maintain remission, 
but the combination also effectively prolongs the lifespan of Infliximab by delaying the 
formation of anti-drug antibodies. Combination therapy, while effective, must be 
carefully monitored due to the increased risk of adverse events associated with it. 
 Although Methotrexate is not very commonly used in the treatment of adult 
Crohn’s Disease, its use in the pediatric population is growing (Herfarth et al., 2017). A 
number of observational studies have suggested a potentially high efficacy if used in 
children, with at least three separate studies showing around a 40% remission rate one-
year into therapy (Djuric et al., 2018; Turner et al., 2007; Uhlen et al., 2006). 
Methotrexate is a particularly potent alternative treatment to thiopurines in pediatric 
patients of very low responsiveness or intolerance to thiopurines(Haisma et al., 2015).  
 Despite the benefits of Methotrexate, it is not often prescribed for the treatment of 
Crohn’s Disease in adults. In a study of 5,420 patients, only 2.1% of patients were 
prescribed Methotrexates, and of these, less than 30% were prescribed Methotrexate as a 
first-line drug (Saibeni et al., 2012). Moreover, of these 112 patients who received 
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Methotrexate treatment, more than one-third experienced adverse events significant 
enough to warrant discontinuation of Methotrexate treatment. Although this number is 
high, it is much lower today due to the introduction of folic acid supplementation during 
methotrexate treatment, which has led to significantly less adverse events being reported 
(Saibeni et al, 2012). Some theories also posit that the low rates of Methotrexate 
prescription are due to the perceived dangers associated with the higher doses of 
Methotrexate used to treat cancers (Herfarth et al., 2017).  
 Because dosage is a concern when it comes to methotrexates, it is important to 
evaluate efficacy of the drug at different dosage levels. As anticipated, a 25 mg dose of 
Methotrexate was associated with a 14% higher rate of patient intolerance than a 15 mg 
dose (Herfarth et al., 2017). In addition to this, some side effects associated with 
Methotrexate use are very common. For example, up to 25% of patients can experience 
nausea during treatment, though this is often mitigated with polypharmacy. More serious 
adverse events associated with Methotrexate use in the treatment of Crohn’s Disease 
include hepatotoxicity, gastrointestinal toxicity, infections, and bone marrow suppression 
(Stein & Hanauer, 2000). The hepatotoxicity is due to the effect of Methotrexates in 
upregulating liver enzymes. Possible liver complications from other conditions such as 
alcoholism, non-alcoholic fatty liver disease, and diabetes must be considered before 
Methotrexate treatment is initiated. Methotrexate should not be used in pregnant women 
due to its teratogenic effects. 
 Overall, Methotrexate performs well in its function as an immunosuppressant 
used to treat Crohn’s Disease. It is an inexpensive alternative to other treatment options 
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and has more than three decades of research underscoring its efficacy and mild adverse 
effects profile. Its ability to prolong the lifespan of TNF-alpha inhibitor treatment also 
makes it an attractive alternative to thiopurines as an immunosuppressant.  
   
DISCUSSION 
The determination of which class of drugs are the most efficacious to prescribe a 
patient in the treatment of their Crohn’s Disease is difficult. A clinician must weigh a 
number of important factors such as genetic screens for the ability to metabolize a drug, 
responsiveness and the potential for loss responsiveness, the age of the patient and the 
duration of the disease, and the degree of progression of the disease. Secondary, but still 
very important factors, include financial access and compliance to drug treatment. In the 
remainder of this analysis, we will discuss each class of medications in relation to one 
another instead of evaluating them as individual entities. It is important to reiterate that 
each case of Crohn’s Disease is unique due to the intersection of risk factors discussed 
throughout the paper. While we will discuss overall efficacy in general terms, each 
patient should always be considered individually. In addition, regardless of which 
treatment option is used, data confirms that earlier access to treatment produces more 
favorable outcomes than later access, on average (Oh et al., 2017).  
 In general, corticosteroid treatment is effective in inducing remission, but it is not 
often used to maintain remission due to the adverse health effects that it causes.  As 
mentioned previously, corticosteroid use is associated with a number of complications, 
including adipose redistribution and lipodystrophy, hyperglycemia, suppressed wound 
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healing, infection, and cardiac abnormalities (Poetker & Douglas, 2010). Thus, care 
should be taken to transition off of corticosteroid treatment as rapidly as possible, in 
favor of other therapeutic alternatives. A review of studies that used thiopurine treatment 
from the onset of diagnosis instead of corticosteroids showed that a 2.0mg/kg dose of 
azathioprine was as effective as a smaller dose of thiopurines combined with 
corticosteroids in achieving and maintain remission over the course of a two year follow 
up period (Qian et al., 2018). This very recent report highlights the potential for the 
removal of corticosteroids from treatment protocols. This is a minor point, however. in 
the sense that corticosteroids are only used for short durations in the normal course of 
treatment anyway.  
While it has become clear that use of corticosteroids in treating Crohn’s Disease 
should be avoided and use only if necessary for acute flare CD events, routine use of 
thiopurines as a standard of care treatment option has also become a growing concern. 
The effectiveness of thiopurine use seems to be less of an issue, compared to the 
associated risks. Research has shown that thiopurine use increases the risk of 
opportunistic viral infections, through immunosuppression, and malignant 
transformation, such as through direct DNA mutation, oncogenic activation, and impaired 
immune surveillance (Axelrad et al., 2016). These side effects associated with thiopurine 
use have been shown to be associated with drug withdrawal, resulting in increased 
discontinuation of medication (Lopez-Sanroman et al., 2017). Thus, although thiopurines 
may display high efficacy in treating Crohn’s Disease, the high number of adverse 
consequences reduces thiopurine effectiveness, as a result of its reduced ability to sustain 
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long-term therapy. Other studies have also investigated the use of thiopurines in 
conjunction with other therapeutics, rather than as a monotherapy.  
Thiopurine use in combination with TNF-alpha inhibitors has been found to 
mitigate the tissue damage observed in Crohn’s Disease (Magro et al., 2014). 
Additionally, optimization of thiopurine therapy prior to withdrawal of TNF-alpha 
inhibitors was shown to reduce relapse and maintained remission in nearly 75% of 
Crohn’s Disease patients (Bohn Thomsen et al., 2018). This brings up the concept of drug 
combination therapy. Instead of using one class of medications, we must investigate 
whether better outcomes be achieved using more than one class of drugs simultaneously 
in a single patient. One potentially large problem with combination therapy is the risk 
sharing adverse events. Each one of these classes of drugs is associated with a hefty 
adverse effects profile. Prescribing a patient two of these classes of drugs is exposing 
them to the ill effects of both. Nevertheless, combination therapy has been used and was 
found to be a very effective means of controlling Crohn’s Disease in patients with 
advanced progression of the disease (Ananthakrishnan et al., 2017). A significant benefit 
above normal treatment was not observed in those with milder forms of Crohn’s Disease. 
Thus, combination therapy may be efficacious in the treatment of those who have a more 
intense disease status, as the relief from treatment may outweigh the potential for adverse 
outcomes down the line.  
In a study directly comparing the outcomes of patients given either TNF-alpha 
inhibitors combined with thiopurines, TNF-alpha inhibitors alone, or thiopurines alone, 
researchers found that thiopurine treatment alone led to lower remission rates than the 
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other two treatments (Colombel et al., 2010). Their findings showed that treatment with 
combination therapy led to the highest rates of remission. This further supports the idea 
that combination therapy may be a very powerful way to achieve remission in patients. 
These findings were contrasted by those of researchers who found no additional efficacy 
in the use of combination treatment over the use of TNF-alpha inhibitors alone 
(Matsumoto et al., 2016). Another 2017 study by Zarubova supported these findings, 
illustrating that the use of TNF-alpha inhibitors prior to ileocecal resection and thiopurine 
treatment did not significantly impact the occurrence endoscopic recurrence (Zarubova et 
al., 2017). The high side effects profiles of each drug also makes combination therapy an 
unattractive option for the majority of patients.  
Beyond monotherapy and combination therapy options, a step-up strategy to 
treating Crohn’s Disease has risen in popularity in recent years. Previously, the treatment 
of Crohn’s Disease had focused on addressing acute symptoms. Currently, the focus on 
treatment has expanded beyond treatment but towards prevention via mucosal healing 
(Gerhard, 2013). Step-up treatment strategies generally follow a stepwise pattern: 
beginning with acute topical steroid treatment, acute systemic steroid treatments, and 
finally immunosuppressants and biologic agents (Gerhard, 2013).  
There are a fair number of studies that cite TNF-alpha inhibitors (and other 
biologics) as being more effective than other medications, whether used in monotherapy, 
step-up therapy, or combination therapy. The Lemann Index (LI) is a measure of 
structural damage in the GI tract. Crohn’s Disease causes tissue damage over time due to 
the inflammatory process and thus causes an increase in the LI. One study found that only 
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TNF-alpha inhibitor use caused a stabilization of the LI score while thiopurine use was 
associated with increased scores. The mean LI score for the TNF-alpha inhibitor group 
was a 6.3 at baseline and a 6.4 score at 29 months follow up. This is in comparison to the 
thiopurine group who averaged a 4.1 score at baseline and a 8.3score at 29 months follow 
up (Bodini et al., 2017). These findings seem to indicate that thiopurines are not able to 
achieve appreciable mucosal healing and that the disease progression was most 
effectively halted through TNF-alpha inhibitor use.  
A large pooled analysis study corroborated these findings by concluding that 
infliximab was superior to azathioprine in inducing steroid-free remission across 13 
randomized control trials (Chande et al., 2016). The same researchers also concluded that 
combination therapy with both drugs was superior to infliximab alone. A third study 
confirmed these findings by showing that 83% of patients receiving the combination 
therapy achieved remission compared to 61% on TNF-alpha monotherapy (Kariyawasam 
et al., 2017). Additional studies have also shown that TNF-alpha inhibitor monotherapy 
leads to the highest rates of remission compared to treatment using other drugs or 
sequential therapy involving a withdrawal of TNF-alpha inhibitor usage (Allocca et al., 
2017; Zhang et al., 2016). In a recent 2016 study by Preda et al., researchers had 
compared the efficacy of adalimumab and infliximab TNF-alpha inhibitors in preventing 
post-operative occurrence of Crohn’s Disease (Preda et al., 2016). Ultimately, they found 
that both adalimumab and infliximab were equally as effective in preventing post-
operative recurrence, with only a 12% re-resection rate and 35% endoscopic recurrence 
rate (Preda et al., 2016).  
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These five are just some of many studies that emphasize the efficacy of using 
some form of TNF-alpha inhibitor treatment over treatments that do not include TNF-
alpha inhibitors. However, there are also some studies that have drawn conclusions that 
do not support this view. In particular, one study evaluating the long-term efficacy of 
combination found that combination therapy only prevented the need for surgery 6% 
more often than those patients receiving monotherapy but this difference was not 
statistically significant (Barnes et al., 2016). It is possible that when looking at a longer-
term outcome such as surgery instead of a 12 month outcome like remission rates, the 
benefit of combination therapy is reduced due to the development of resistance or loss of 
responsiveness to the drugs. In a separate study, researchers looked at the rates of 
postoperative recurrence of Crohn’s Disease among those patients that were involved in 
either TNF-alpha inhibitor monotherapy or thiopurine monotherapy. These researchers 
found that postoperative recurrence occurred in nearly 30% of patients on TNF-alpha 
monotherapy and 33% of patients on thiopurine monotherapy (Lopez-Sanroman et al., 
2017). These results indicate that there was no difference in efficacy of either drug in 
maintaining postoperative remission. 
 
CONCLUSION 
The treatment of Crohn’s Disease is surprisingly complex and it is unlikely, given 
the current status of medicine and pharmacy, that any singular treatment will be sufficient 
for a patient. Many patients will require some form of combination therapy or have to 
discontinue one therapy in favor of another. Many patients will still require surgical 
 59 
intervention in order to prevent fatal complications. The risks, adverse events, and 
outcomes associated with untreated Crohn’s Disease are poor. While the current 
pharmacological options are not perfect, they have given patients an opportunity to live a 
much healthier and normal life. 
Despite having over a century of exposure to Crohn’s Disease, much has yet to be 
learned about the etiology and pharmacotherapy of the disease. Many of the published 
studies produce conflicting results and draw contradictory conclusions, making it difficult 
to evaluate the best treatment options available right now. The current options for the 
medical treatment and management of Crohn’s Disease is incomplete. Among the options 
available at this time, biologics may represent the best option for the majority of patients. 
A large portion of the current research points towards a higher efficacy of biologics over 
other forms of treatment. These classes of drugs have also had a sizable amount of 
research and development invested into it them the last decade. This makes TNF-alpha 
inhibitors, and especially Vedolizumab and Ustekinumab, very attractive candidates for 
the treatment of Crohn’s Disease.  
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